AP1246A - Substituted pyrazoles as p38 Kinase inhibitors. - Google Patents

Substituted pyrazoles as p38 Kinase inhibitors.

Info

Publication number
AP1246A
AP1246A APAP/P/1999/001715A AP9901715A AP1246A AP 1246 A AP1246 A AP 1246A AP 9901715 A AP9901715 A AP 9901715A AP 1246 A AP1246 A AP 1246A
Authority
AP
ARIPO
Prior art keywords
kinase inhibitors
substituted pyrazoles
pyrazoles
substituted
class
Prior art date
Application number
APAP/P/1999/001715A
Other versions
AP9901715A0 (en
Inventor
Ashok Anantanarayan
Michael Clare
Paul W Collins
Joyce Zuowu Crich
Rajesh Devraj
Daniel L Flynn
Lifeng Geng
Gunnar J Hanson
Francis J Koszyk
Shuyuan Liao
Richard A Partis
Shashidhar N Rao
Shaun Raj Selness
Michael J South
Michael A Stealey
Richard M Weier
Xiangdong Xu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AP9901715A0 publication Critical patent/AP9901715A0/en
Application granted granted Critical
Publication of AP1246A publication Critical patent/AP1246A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by formula (i)wherein r1, r2, r3 and r4 are as described in the specification
APAP/P/1999/001715A 1997-05-22 1998-05-22 Substituted pyrazoles as p38 Kinase inhibitors. AP1246A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
PCT/US1998/010436 WO1998052940A1 (en) 1997-05-22 1998-05-22 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
AP9901715A0 AP9901715A0 (en) 1999-12-31
AP1246A true AP1246A (en) 2004-02-07

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001715A AP1246A (en) 1997-05-22 1998-05-22 Substituted pyrazoles as p38 Kinase inhibitors.

Country Status (24)

Country Link
EP (1) EP1000055A1 (en)
JP (1) JP2002508754A (en)
KR (1) KR20010012854A (en)
CN (1) CN1264377A (en)
AP (1) AP1246A (en)
AU (1) AU754830C (en)
BG (1) BG64313B1 (en)
BR (1) BR9809147A (en)
CA (1) CA2291115A1 (en)
EA (1) EA003925B1 (en)
EE (1) EE9900527A (en)
GE (1) GEP20033053B (en)
HU (1) HUP0001880A3 (en)
ID (1) ID22982A (en)
IL (1) IL132991A (en)
IS (1) IS5257A (en)
NO (1) NO995695L (en)
NZ (1) NZ501112A (en)
OA (1) OA12981A (en)
PL (1) PL337020A1 (en)
SK (1) SK157899A3 (en)
TR (1) TR200000235T2 (en)
WO (1) WO1998052940A1 (en)
ZA (1) ZA984358B (en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (en) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US20020156104A1 (en) 1997-06-13 2002-10-24 Jerry L. Adams Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000019824A1 (en) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Novel treatment for stroke management
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
EP1140916B1 (en) 1998-12-16 2002-11-13 Aventis Pharma Limited Heteroaryl-cyclic acetals
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
KR100711538B1 (en) * 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 Aminopyrazole derivatives
IL145508A0 (en) 1999-03-26 2002-06-30 Euro Celtique Sa Aryl substituted pyrazole, imidazole, oxazole, thiazole and pyrrole derivatives and pharmaceutical compositions containing the same
CN1281604C (en) * 1999-06-03 2006-10-25 帝国脏器制药株式会社 Substituted pyrazole compounds
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
DE60039616D1 (en) * 1999-08-13 2008-09-04 Vertex Pharma INHIBITORS OF THE C-JUN N-TERMINAL KINASE (JNK) AND OTHER PROTEIN KINASES
WO2001030154A2 (en) * 1999-10-25 2001-05-03 Basf Aktiengesellschaft Agrochemical compositions containing pyrazoles and use thereof as fungicidal plant protection agents
DE19952147A1 (en) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma New cyclopropanes, pharmaceutical compositions containing these compounds and process for their preparation
ES2230171T3 (en) 1999-11-23 2005-05-01 Smithkline Beecham Corporation 3,4-DIHIDRO- (1H) QUINAZOLIN-2-ONA COMPOUNDS AS CSBP / P38 QUINASA INHIBITORS.
DE60023025T2 (en) 1999-11-23 2006-07-13 Smithkline Beecham Corp. 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS
JP2003514900A (en) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション 3,4-Dihydro- (1H) -quinazolin-2-one compounds as CSBP / p38 kinase inhibitors
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazoles
WO2002062792A1 (en) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Jnk inhibitor
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
EP2048142A3 (en) 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
SI1397364T1 (en) 2001-05-24 2007-12-31 Lilly Co Eli Novel pyrrole derivatives as pharmaceutical agents
YU30504A (en) 2001-09-25 2006-08-17 Pharmacia Corporation Process for making substituted pyrazoles
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
RU2277534C2 (en) * 2001-09-25 2006-06-10 Фармация Корпорейшн Method for preparing substituted pyrazoles
TW200400960A (en) * 2002-06-05 2004-01-16 Pharmacia Corp Novel pyrazoles and their use as P38 kinase inhibitors
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
WO2004016592A1 (en) 2002-08-14 2004-02-26 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
RU2332412C2 (en) 2003-02-07 2008-08-27 Дайити Фармасьютикал Ко., Лтд. Pyrazole derivatives
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AU2005273612B2 (en) 2004-08-12 2010-10-14 Pfizer Inc. Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
PE20060777A1 (en) 2004-12-24 2006-10-06 Boehringer Ingelheim Int INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
ATE538118T1 (en) 2004-12-28 2012-01-15 Aska Pharm Co Ltd PYRIMIDINYLISOXAZOLE DERIVATIVE
CA2643066A1 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
US20090192164A1 (en) * 2006-06-28 2009-07-30 Aska Pharmaceutical Co., Ltd. Treating agent of inflammatory bowel disease
JP5244591B2 (en) 2006-06-28 2013-07-24 あすか製薬株式会社 Pyridylisoxazole derivatives
KR101434706B1 (en) 2007-02-16 2014-08-26 아스카 세이야쿠 가부시키가이샤 Pharmaceutical composition containing fine particle oil-based suspension
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US20100144756A1 (en) * 2007-07-13 2010-06-10 Bolea Christelle Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
US8859580B2 (en) 2007-11-16 2014-10-14 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
CL2009000904A1 (en) * 2008-04-21 2010-04-30 Shionogi & Co Compounds derived from cyclohexyl sulfonamides having antagonist activity at the npy y5 receptor, pharmaceutical composition and pharmaceutical formulation comprising them.
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
EP2324008B1 (en) 2008-07-24 2012-05-09 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
CA2735204C (en) * 2008-08-25 2017-06-20 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
WO2010045764A1 (en) * 2008-10-23 2010-04-29 Lonza Ltd Process for the synthesis of substituted pyrazoles
RU2528406C2 (en) * 2008-11-21 2014-09-20 Раквалиа Фарма Инк. New pyrazole-3-carboxamide derivative possessing antagonist activity on 5-нт2в receptor
US8703765B2 (en) 2009-06-02 2014-04-22 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2011011123A1 (en) 2009-06-11 2011-01-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
EA201200321A1 (en) * 2009-08-26 2012-09-28 Новартис Аг TETRA-SUBSTITUTED HETEROARRYL COMPOUNDS AND THEIR USE AS MDM2 AND / OR MDM4 MODULATORS
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Protein kinase inhibitors
EP2308866A1 (en) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles and their use as fungicides
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
AU2011209234B2 (en) 2010-01-27 2015-05-07 Nerviano Medical Sciences S.R.L. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
AR081810A1 (en) 2010-04-07 2012-10-24 Bayer Cropscience Ag BICYCLE PIRIDINYL PIRAZOLS
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
JP5938038B2 (en) 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ Derivatives of pyrazolophenyl-benzenesulfonamide compounds and their use as antitumor agents
EP3181133B1 (en) * 2010-12-20 2019-07-24 Pfizer Inc Novel fused pyridine compounds as casein kinase inhibitors
AR086992A1 (en) 2011-06-20 2014-02-05 Bayer Ip Gmbh TIENILPIRI (MI) DINILPIRAZOLES
US8735585B2 (en) 2011-08-17 2014-05-27 Boehringer Ingelheim International Gmbh Indenopyridine derivatives
IN2014CN02475A (en) 2011-10-06 2015-06-19 Bayer Ip Gmbh
UA114490C2 (en) 2011-10-06 2017-06-26 Байєр Інтеллектуал Проперті Гмбх Heterocyclylpyri(mi)dinylpyrazole as fungicidals
DE102011115525A1 (en) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Two-part bottle packaging device for containing pharmaceutical tablets or capsules, has bottle body and bottle base, where bottle is closed with pressure lock or with pressure lock injected at bottle body or with separate rotary lock
JP6150813B2 (en) 2011-11-11 2017-06-21 ノバルティス アーゲー Method for treating proliferative diseases
CA2856406C (en) 2011-11-23 2020-06-23 Novartis Ag Pharmaceutical formulations
EP2968330B1 (en) 2013-03-15 2021-09-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US9573904B2 (en) * 2013-12-12 2017-02-21 Sumitomo Chemical Company, Limited Aromatic compound and use thereof
CN104829536B (en) * 2015-05-04 2017-12-29 陕西科技大学 A kind of Phenylpyrazole carboxylic acid compound and its synthetic method for having antitumor activity
WO2016189877A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
CN112457255B (en) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 Compounds and their use for treating cancer
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020124397A1 (en) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
WO2021138540A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
EP3978487A1 (en) * 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
WO2022146698A1 (en) * 2020-12-29 2022-07-07 Revolution Medicines, Inc. Sos1 inhibitors and uses thereof
WO2025231152A1 (en) * 2024-04-30 2025-11-06 The Cleveland Clinic Foundation Compounds and methods for restoring beta-adrenergic receptor function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996003385A1 (en) * 1994-07-21 1996-02-08 G.D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2753659B2 (en) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 Pyrazole derivatives
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
JP3734180B2 (en) * 1994-12-28 2006-01-11 エーザイ株式会社 New pyrazole derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
WO1996003385A1 (en) * 1994-07-21 1996-02-08 G.D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
ZA984358B (en) 1999-05-24
NO995695D0 (en) 1999-11-19
EA003925B1 (en) 2003-10-30
BR9809147A (en) 2000-08-01
SK157899A3 (en) 2000-08-14
BG64313B1 (en) 2004-09-30
AU754830C (en) 2004-02-12
EP1000055A1 (en) 2000-05-17
CN1264377A (en) 2000-08-23
GEP20033053B (en) 2003-08-25
WO1998052940A1 (en) 1998-11-26
HUP0001880A3 (en) 2002-03-28
EE9900527A (en) 2000-06-15
IL132991A0 (en) 2001-03-19
EA199900953A1 (en) 2000-10-30
OA12981A (en) 2006-10-13
BG103964A (en) 2000-08-31
ID22982A (en) 1999-12-23
AU754830B2 (en) 2002-11-28
IL132991A (en) 2005-11-20
NO995695L (en) 2000-01-21
AU7588398A (en) 1998-12-11
PL337020A1 (en) 2000-07-31
IS5257A (en) 1999-11-19
JP2002508754A (en) 2002-03-19
TR200000235T2 (en) 2000-05-22
NZ501112A (en) 2002-10-25
CA2291115A1 (en) 1998-11-26
KR20010012854A (en) 2001-02-26
HUP0001880A2 (en) 2001-03-28
AP9901715A0 (en) 1999-12-31

Similar Documents

Publication Publication Date Title
AP2001002172A0 (en) Substituted pyrazoles as p38 kinase inhibitors
TR200000235T2 (en) Pyrazoles substituted as p38 kinase inhibitors.
BR9809451A (en) Pyrazoles substituted with 3 (5) -heteroaryl as inhibitors of p38 kinase.
MY119800A (en) Pyridine derivatives
AU3328499A (en) Phthalazinone pde iii/iv inhibitors
MY133392A (en) Novel substituted pyrazole derivatives
NO942618L (en) Imidazole derivatives and their use as cytokine inhibitors
PL327735A1 (en) Novel substituted derivatives of imidazole
MXPA02011977A (en) Substituted pyridine herbicides.
IL107947A0 (en) Substituted pyrazoles
MY128485A (en) Pesticidal 1-arylpyrazoles
DE60023025D1 (en) 3,4-DIHYDRO- (1H) CHINAZOLIN-2-ON COMPOUNDS AS CSBP / P39 KINASE INHIBITORS
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
ATE291018T1 (en) PYRAZOLE COMPOUNDS AND THEIR USES
GB0308201D0 (en) Novel compounds
PT920426E (en) NEW TIAZOLE DERIVATIVES WITH PHOSPHODIESTERASE INHIBITOR EFFECT
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
MX9702203A (en) Substituted pyrazolyl-pyrazole derivatives, processes for their preparation and their use as agents with herbicidal action.
DE60036558D1 (en) PHTHALAZINONE DERIVATIVES AS PDE 4 HEMMER
AU2001296699A1 (en) Condensed pyrazindione derivatives as pde inhibitors
MXPA03000887A (en) Fused heterocyclic derivatives as phosphodiesterase inhibitors.
MY141481A (en) Substituted pyrazoles as p38 kinase inhibitors
IL141009A0 (en) N-substituted azabicycloheptane derivatives, production and use thereof
SI0937075T1 (en) New Imidazo- and Oxazolopyridines as Phosphodiesterase Inhibitors.